Managing a first episode psychotic mania represents one of the most critical decision-making junctures in clinical psychiatry. Clinicians frequently encounter diagnostic ambiguity, severe behavioural disruption, and intense distress during this index presentation. Furthermore, early therapeutic choices determine long-term functional recovery, neuroprogression, and psychiatric relapse trajectories. Although clinicians routinely prescribe second-generation antipsychotics to manage acute agitation and psychosis, optimal long-term maintenance remains debated. A landmark investigation from the BD-CAUSAL Collaboration provides compelling real-world evidence comparing mood stabiliser monotherapy, second-generation antipsychotic monotherapy, and combination maintenance therapy.

Target Trial Emulation in First Episode Psychotic Mania

Randomised clinical trials evaluating continuation therapy following initial mania remain exceptionally difficult to conduct. Consequently, researchers face substantial ethical and logistical hurdles when randomising young individuals experiencing acute psychosis. To overcome these observational challenges, investigators implemented a pragmatic target trial emulation using longitudinal data from the international BD-CAUSAL Collaboration. This robust methodology systematically emulates the design of a prospective trial, thereby reducing immortal time bias and confounding by indication.

The research team gathered data across established clinical centres in North America, Chile, and Spain between 2006 and 2021. Eligible participants included individuals aged 16 years or older presenting with a diagnosed manic episode with psychotic features under DSM-5 criteria. Additionally, candidates were treated at specialized first-episode psychosis clinics and had not received recent mood stabilisers or second-generation antipsychotics in the prior three months. Researchers assigned eligible person-visits to one of three active continuation arms: mood stabiliser monotherapy, second-generation antipsychotic monotherapy, or combination therapy. Furthermore, the investigators followed cohorts for up to two years to evaluate relapse events, defined as psychiatric hospital admission or emergency department attendance. Through pooled logistic regression, the team rigorously adjusted for baseline characteristics and time-varying clinical confounders.

Key Findings Across Maintenance Treatment Arms

The analyzed cohort comprised 371 individuals representing 465 eligible treatment initiations. Within this sample, 62 percent were male and 38 percent were female, with a median participant age of 22 years. Notably, 42 percent of patients required acute psychiatric rehospitalisation over a median follow-up period of 19.8 months. This high relapse frequency highlights the extreme vulnerability of young adults following their first severe affective episode.

When evaluating comparative endpoints, the two-year risk of psychiatric hospitalisation or emergency department presentation reached 49.5 percent in the second-generation antipsychotic monotherapy group. In contrast, patients receiving mood stabiliser monotherapy experienced a substantially lower two-year event risk of 42.3 percent. Similarly, individuals receiving combination therapy demonstrated a two-year failure risk of 42.2 percent. Statistical comparisons confirmed that mood stabiliser monotherapy significantly outperformed second-generation antipsychotic monotherapy, yielding a risk difference of minus 7.3 percent and a risk ratio of 0.82. In addition, combination therapy achieved an identical risk reduction of minus 7.4 percent and a risk ratio of 0.82 relative to antipsychotic monotherapy. Interestingly, the investigation demonstrated similar therapeutic efficacy between mood stabiliser monotherapy and dual combination treatment.

Clinical Implications for Bipolar Maintenance Therapy

These findings offer crucial therapeutic direction for psychiatric practice globally and within resource-conscious healthcare environments. Modern treatment trends often show heavy reliance on second-generation antipsychotics due to their rapid sedative and antimanic effects during acute crises. However, the study indicates that relying solely on antipsychotic monotherapy for ongoing maintenance increases the likelihood of psychiatric relapse. Therefore, psychiatrists should deliberately integrate mood stabilisers into early therapeutic regimens rather than depending exclusively on long-term antipsychotics.

Furthermore, traditional mood stabilisers such as lithium and valproate offer unique neuroprotective, anti-suicidal, and long-term mood-buffering benefits. While clinicians often continue acute antipsychotic regimens into maintenance out of convenience, these data emphasize that mood stabiliser-based strategies prevent subsequent hospitalisation more effectively. Moreover, the finding that combination therapy did not confer superior prophylaxis over mood stabiliser monotherapy carries major clinical relevance. Consequently, clinicians may successfully de-escalate patients from combination therapy to mood stabiliser monotherapy once acute psychotic agitation subsides. This rational simplification minimizes adverse effects without compromising relapse prevention.

Balancing Tolerability, Adherence, and Long-Term Safety

Long-term pharmacotherapy for young adults navigating bipolar I disorder requires careful balancing of clinical efficacy against side-effect burden. Second-generation antipsychotics carry significant liabilities, including rapid metabolic syndrome, severe weight gain, hyperprolactinemia, and extrapyramidal symptoms. Over time, these distressing side effects frequently trigger treatment non-adherence, which precipitates preventable psychiatric readmission. Hence, reducing antipsychotic exposure during maintenance provides measurable physical health benefits.

Conversely, mood stabilisers introduce distinct monitoring obligations that healthcare practitioners must supervise proactively. Lithium maintenance demands regular assessment of renal function, thyroid panels, and serum trough levels to avoid toxicity. Similarly, valproate requires liver function testing, hematological monitoring, and stringent avoidance in female patients of childbearing potential due to major teratogenic risks. In low- and middle-income clinical settings like India, mood stabiliser generic preparations remain remarkably affordable and accessible. However, successful maintenance therapy depends on robust therapeutic drug monitoring and empathetic psychoeducation. By explaining the prophylactic necessity of mood stabilisers, clinicians help patients achieve durable functional recovery while preserving their metabolic wellness.

Addressing Common Clinical Dilemmas in Practice

Practicing physicians frequently encounter difficult management questions when stabilizing young patients who have achieved acute remission. A primary dilemma involves the safe timeline for tapering antipsychotic medications after psychotic mania remits completely. Often, practitioners maintain high-dose antipsychotics indefinitely because they fear imminent psychotic decompensation. Nevertheless, current evidence suggests that clinicians can thoughtfully taper adjunctive antipsychotics once therapeutic mood stabiliser levels are established and symptoms remain quiescent.

Additionally, clinicians must decide between lithium and anticonvulsants when selecting primary mood stabilisation. Lithium remains the gold standard for preventing both manic and depressive recurrences and significantly diminishes completed suicide risk. In contrast, sodium valproate serves as an effective alternative for patients presenting with mixed features or irritable mania, provided teratogenic precautions are respected. Furthermore, physicians must actively address patient resistance regarding long-term daily medications. Early psychoeducation addressing illness trajectory, warning signs of recurrence, and lifestyle stability can profoundly increase compliance. Thus, structuring regular outpatient follow-ups allows clinical teams to identify subthreshold affective symptoms early, preventing catastrophic full-blown manic relapses.

Future Research Directions and Evidence Gaps

Although target trial emulation provides robust causal inferences from real-world data, pragmatic randomised controlled trials remain essential to corroborate these observations. Future investigations should evaluate whether specific second-generation antipsychotics exhibit distinct maintenance profiles compared with older atypical agents. In addition, researchers should examine the differential prophylactic efficacy between lithium and valproate as distinct monotherapy arms in first-episode psychotic cohorts.

Furthermore, future trials must incorporate standardized patient-reported outcome measures, cognitive assessments, and metabolic markers alongside psychiatric hospitalisation metrics. Understanding how maintenance choices influence neurocognitive functioning, career attainment, and overall quality of life will better refine personalized treatment algorithms. In summary, the BD-CAUSAL Collaboration study provides persuasive evidence that prioritizing mood stabilisers early after a first episode of psychotic mania significantly lowers the risk of subsequent psychiatric readmission.

Frequently Asked Questions

Why are mood stabilisers preferred over antipsychotic monotherapy for maintenance?

Mood stabilisers significantly reduce two-year psychiatric hospitalisation and emergency department presentation risks compared to second-generation antipsychotic monotherapy. Furthermore, agents like lithium offer unique long-term neuroprotective properties, suicide prevention benefits, and superior prophylaxis against future manic and depressive relapses, whereas maintenance antipsychotics carry substantial long-term metabolic and neurological risks.

Is combination therapy more effective than mood stabiliser monotherapy alone?

Current target trial emulation findings indicate that combination therapy does not provide superior relapse prevention compared with mood stabiliser monotherapy alone. Although combination therapy effectively controls acute psychotic mania, clinicians can safely taper adjunctive antipsychotic agents once stabilization occurs, thereby avoiding redundant adverse effects while maintaining optimal mood stability.

What baseline monitoring is required before initiating mood stabilisers?

Before initiating lithium, clinicians must obtain baseline serum creatinine, estimated glomerular filtration rate, electrolytes, thyroid function tests, and an electrocardiogram. Conversely, starting valproate requires liver function tests, complete blood counts, and pregnancy testing. Clinicians should maintain regular therapeutic drug monitoring to ensure serum concentrations remain within safe therapeutic ranges.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. Szmulewicz AG et al. Comparative effectiveness of mood stabiliser monotherapy versus second-generation antipsychotic monotherapy versus combination therapy for continuation and maintenance treatment after a first episode of psychotic mania in North America, Chile, and Spain: a target trial emulation using data from the BD-CAUSAL Collaboration. Lancet Psychiatry. 2026 Oct. doi: 10.1016/S2215-0366(26)00239-7. PMID: 42716056.


2. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170.


3. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-395.